

1 **Nonlinear relationship between ionized calcium and 28-day**
2 **mortality in patients with sepsis: A retrospective cohort**
3 **study from MIMIC-IV database**

4 Zhanyao Liang¹, Yunting Chen², Yuanshen Zhou³, Congqi Hu⁴, Lu Chen⁵, Fangfang
5 Zhu^{2*}

6 ¹The Second Clinical Medical College, Guangzhou University of Chinese Medicine,
7 Guangzhou 510000, China

8 ²Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine,
9 Guangzhou 510000, China

10 ³Department of Cardiovascular, Guangdong Provincial Hospital of Chinese Medicine,
11 Guangzhou 510000, China

12 ⁴Department of Rheumatology, Baiyun Hospital of The First Affiliated Hospital of
13 Guangzhou University of Chinese Medicine, Guangzhou 510000, China

14 ⁵Department of Good Clinical Practice, The Affiliated Hospital of Guizhou Medical
15 University, Guiyang 550001, China

16 **ABSTRACT**

17 *Background:* This study aimed to investigate the linear and nonlinear relationships
18 between ionized calcium levels and 28-day mortality in patients with sepsis in the
19 intensive care unit (ICU) and to provide clinicians with a direction for laboratory index
20 testing and a basis for a calcium supplementation program.

21 *Methods:* The data of patients with sepsis were extracted from the Medical Information
22 Mart for Intensive Care (MIMIC-IV) database, iCa served as the exposure variable, and
23 28-day mortality served as the outcome variable. The relationship between iCa and 28-
24 day mortality was investigated using multivariate binary logistic regression models,
25 with adjustment for covariates. A generalized additive model (GAM) and smoothed
26 curve fitting were used to investigate the non-linear relationship between iCa and 28-
27 day mortality. A two-piecewise linear model was used to calculate the OR and 95% CI
28 on either side of the inflection point.

29 *Results:* Patients with sepsis (n = 20,417) were included in the analysis, with an overall
30 28-day mortality rate of 19.73%. Sepsis patients were grouped into quartiles (Q1-Q4)
31 according to ionized calcium levels, and after complete adjustment, the short-term

*Corresponding author. Department of Gynecology, Guangdong Provincial Hospital of Chinese
Medicine, 111 Dade Road, Guangzhou 510000, Guangdong, China.

E-mail address: zhufangfang0807@126.com (F. Zhu).

32 mortality rate of sepsis patients in Q2–Q4 was significantly lower than that in the Q1
33 group (OR:0.78, 95% CI: 0.70–0.87. OR: 0.74, 95% CI: 0.66–0.83. OR: 0.81, 95% CI:
34 0.72–0.9. iCa and 28-day mortality displayed a U-shaped relationship among patients
35 with sepsis. When iCa levels were less than 1.14 mmol/L, each unit increase
36 corresponded to a 79% reduction in the risk of 28-day sepsis mortality(OR: 0.21, 95%
37 CI: 0.13-0.35). Conversely, when iCa exceeded 1.14 mmol/L, each unit increase was
38 linked to an 85% increase in the 28-day mortality risk (OR: 1.85, 95% CI: 1.08-3.16).
39 *Conclusion:* The relationship between iCa and 28-day mortality in patients with sepsis
40 showed a u-shaped curve with an inflection point of 1.14 mmol/L, which is in the range
41 of mild hypocalcemia.
42 **Keywords:** ionized calcium, sepsis, 28-Day mortality, MIMIC-IV, retrospective study,
43 nonlinear relationship.
44

45 1. Introduction

46 Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response
47 to infection ^[1], accounts for approximately 19.7% of all global deaths ^[2]. Studies
48 estimate that there are approximately 31.5 million new cases of sepsis and 5.3 million
49 deaths worldwide each year, making it a major global public health problem ^[3].

50 Despite extensive efforts to discover new treatments and understand the underlying
51 causes of sepsis, the mortality rate associated with this condition has not decreased ^[4,5].
52 One challenge is the lack of reliable predictors for sepsis, which hinders accurate
53 prediction of prognosis and leads to inadequate statistical power in clinical trials for
54 new treatments. Therefore, it is crucial to explore simple and effective biomarkers to
55 determine the prognosis of sepsis.

56 Abnormal serum calcium levels may be a marker of disease severity in critical
57 illness ^[6-8]. Hypocalcemia has been frequently observed in sepsis syndrome ^[9], and
58 several studies have reported a statistically significant negative correlation between
59 serum calcium levels and mortality rates in patients diagnosed with sepsis ^[10-12].
60 However, other studies have reported that only extreme outliers of calcium levels are
61 associated with sepsis mortality ^[13,14], so what is the real role of calcium in sepsis?

62 We hypothesize that inconsistencies in the findings of the aforementioned studies
63 may be due to the following: (1) Some of the exposure factors in the studies were total
64 calcium and some were ionized calcium (iCa). Approximately 50% of the total calcium
65 is iCa, which is biologically active and less susceptible to other factors (e.g., albumin
66 levels); therefore, iCa is preferred for assessment if available (2). Small sample sizes
67 and inadequate adjustment for confounding factors resulted in less convincing
68 conclusions. Therefore, this study used the extensive US multicenter sepsis database,
69 Medical Information Mart for Intensive Care (MIMIC-IV), to investigate the
70 association between iCa and the 28-day mortality risk in sepsis. The substantial sample
71 size and extensive database information provided valuable statistical power, ensuring
72 more robust and dependable findings that enhance our understanding of the relationship
73 between iCa and the 28-day mortality risk in sepsis.

74 2. Methods

75 *2.1 Study population*

76 This study investigated health-related data obtained from the Medical Information
77 Marketplace for Intensive Care IV (MIMIC-IV) database, which consists of extensive,
78 high-quality medical records of patients in the Beth Israel Deaconess Medical Center
79 (BIDMC), and was developed and managed by the MIT Computational Physiology
80 Laboratory ^[15]. The database is available for free download upon completion of an
81 accredited course on its official website. Author (Lu Chen (RECORD 35931520)
82 obtained access to the database and was responsible for data extraction. This study
83 complied with the reports of studies conducted using the observation routine collected
84 health data (RECORD) statement.

85 In this study, patients with sepsis attending BIDMC during 2008–2019 were
86 extracted from the MIMIC-IV database based on ICD-9 codes recorded in the database
87 to study the association between iCa levels and 28-day mortality in patients with sepsis.
88 Patients with missing information on exposure variables were not included in this study.

89 Based on our clinical experience and reports in the literature, potential variables
90 that were also analyzed included: demographic factors: gender (male/female), age at
91 admission (years), ethnicity, charlson comorbidity index, SOFA score, heart rate,
92 respiratory rate, and temperature on admission, use of mechanical ventilation, use of
93 dialysis, use of norepinephrine, use of glucocorticosteroids (dexamethasone,
94 methylprednisolone, hydrocortisone), use of vasoactive drugs (dopamine, dobutamine),
95 immunoglobulins, antibiotics (carbapenem, cephalosporins, cillin-based drug,
96 vancomycin).

97 *2.2 Statistical analysis*

98 Continuous variables are expressed as mean \pm standard deviation (Gaussian
99 distribution) or median (minimum, maximum) (skewed distribution), and categorical
100 variables are expressed as rates. Because this was a cohort study, we divided the
101 patients into 4 equal groups according to their iCa levels and observed the distribution
102 of their baseline data among the different groups. One-way ANOVA (Gaussian
103 distribution), Kruskal-WallisH (skewed distribution) test, and chi-square test
104 (categorical variables) were used to determine any statistical differences between the
105 means and proportions of the groups.

106 We used univariate and multivariate binary logistic regression models to observe
107 the association between iCa levels and 28-day mortality in patients with sepsis. We
108 used three models with a gradual degree of adjustment, including the unadjusted model
109 (no covariates were adjusted, Model 1), the Minimally-adjusted model (adjusted only
110 for demographic factors, Model 2), the Fully-adjusted model (adjusted for all the
111 covariates presented in Table 1, Model 3) and present the Odds ratio value (OR) and
112 95% confidence intervals are presented.

113 In addition, for the sensitivity analysis, we transformed calcium ion levels from a
114 continuous variable to a categorical variable (quartile) and calculated *P* for trend, with
115 the aim of observing whether the results were robust when calcium ion levels were used
116 as a continuous variable versus as a categorical variable.

117 Because iCa levels are continuous variables, the possibility of a nonlinear
118 association cannot be excluded. Given the incompetence of the binary logistic
119 regression model in dealing with nonlinear associations, we used a generalized additive
120 model (GAM) and smoothed curve fitting to observe the association between ionic
121 calcium levels and 28-day mortality in sepsis. If a nonlinear association existed, we first
122 calculated the inflection point values using a recursive algorithm, and then calculated
123 OR values and 95% confidence intervals on both sides of the inflection point using a
124 two-piecewise linear model.

125 All analyses were performed using the statistical packages R ([http://www.R-](http://www.R-project.org)
126 [project.org](http://www.R-project.org), The R Foundation) and EmpowerStats (<http://www.mpowerstats.com>,
127 X&Y Solutions, Inc, Boston, MA). *P* values < 0.05 (two-sided) were considered
128 statistically significant.

129 **3. Results**

130 *3.1 Screening process*

131 In this study, we enrolled 377,207 patients from the MIMIC-IV database. Among
132 these, 342,197 were non-septic patients, while 14,593 had missing information on iCa.
133 Consequently, 20,417 cases were considered for the final analysis. The flow chart of
134 patient selection is depicted in Fig .1.

135 *3.2 Baseline characteristics*

136 Patient baseline characteristics are summarized in Table 1. iCa levels in the entire
137 population were segmented into four groups (Q1 to Q4) based on quartile divisions.
138 Trends in the distribution of each variable across different subgroups were observed
139 following this segmentation. Analysis revealed that, relative to the Q1 group, patients
140 in the Q2, Q3, and Q4 groups were typically older, had a higher representation of white
141 ethnicity, a higher Charlson Comorbidity Index, and more frequent use of
142 dexamethasone and dopamine. These groups also exhibited lower SOFA scores, heart
143 rate, and respiratory rate. They received a lower percentage of treatments such as
144 methylprednisolone, hydrocortisone, norepinephrine, intravenous gammaglobulin,
145 cephalosporins, cillin-based drugs, carbapenems, vancomycin, mechanical ventilation,
146 and dialysis and demonstrated a lower 28-day mortality rate. The 28-day mortality rate
147 for patients with sepsis was 19.73%.

148 *3.3 Relationship between iCa and 28-day mortality in patients with sepsis using non-* 149 *adjusted and adjusted models*

150 Various covariate adjustment strategies were employed to elucidate the relationship
151 between iCa and 28-day mortality in patients with sepsis. The non-adjusted and
152 adjusted models are detailed in Table 2. The non-adjusted model revealed that for each
153 unit increase in iCa, the 28-day mortality risk in patients with sepsis was reduced by
154 86% (OR: 0.14, 95%CI: 0.11-0.19, *P*<0.001). After adjusting for sex, age at admission,
155 and ethnicity in Model 1, the trend remained consistent (OR: 0.13, 95%CI: 0.09-0.17,
156 *P* <0.001). In Model 2, which was adjusted for all covariates listed in Table 1, the 28-

157 day mortality risk was reduced by 41% (OR: 0.59, 95%CI: 0.43-0.82, $P < 0.001$).
158 Sensitivity analysis was also conducted with iCa treated as a categorical variable
159 (quartile), and a similar trend was observed (P for trend < 0.0001).

160 *3.4 Non-linear relationship between iCa and 28-day mortality*

161 A generalized additive model and smoothed curve fitting were used to examine the
162 nonlinear relationship between iCa and 28-day mortality. The findings suggested a U-
163 shaped association between iCa and 28-day mortality after adjusting for covariates (The
164 adjustment strategy aligns with model2 in Table 2) (Refer to Fig .2). The inflection
165 point for iCa was calculated to be 1.14 mmol/L using a two-piecewise linear model and
166 a recursive algorithm. For iCa levels less than 1.14 mmol/L, each unit increase
167 corresponded to a 79% reduction in the risk of 28-day sepsis mortality (OR: 0.21, 95%
168 CI: 0.13 to 0.35, $P < 0.0001$). Conversely, when iCa exceeded 1.14 mmol/L, each unit
169 increase was linked to an 85% rise in the 28-day mortality risk (OR: 1.85, 95% CI: 1.08
170 to 3.16, $P < 0.05$) (Table 3).

171 **4. Discussion**

172 In the present study, we evaluated the association between iCa levels and 28-day
173 mortality in patients with sepsis from the MIMIC IV database, which, to the best of our
174 knowledge, is the largest sample size study on iCa and short-term mortality in sepsis.
175 The results of this study indicate that iCa levels are independently associated with 28-
176 day mortality in patients with sepsis. They remained strongly correlated even after
177 correction for confounding risk factors. Importantly, by GAM modeling and smoothed
178 curve fitting, we found a U-shaped relationship between iCa levels and 28-day mortality
179 in patients with sepsis, i.e., when iCa levels were less than 1.14 mmol/L, each unit
180 increase corresponded to a 79% reduction in the risk of 28-day sepsis mortality.
181 Conversely, when iCa exceeded 1.14 mmol/L, each unit increase was linked to an 85%
182 increase in the 28-day mortality risk.

183 The rapid progression and high mortality of sepsis implies the necessity of
184 identifying prognostic indicators associated with its outcome. It is recommended that
185 scholars further explore serum markers and prognostic correlates to help clinicians
186 intervene early ^[16,17]. Calcium is an essential trace element in the human body that is
187 responsible for physiological functions including cell signaling, neurotransmission, and
188 muscle contraction ^[6,18,19]. Calcium disorders are uncommon in the general population,
189 except in special cases (e.g., renal failure), and are therefore often neglected ^[20,21].
190 Nevertheless, calcium derangements in sepsis are prevalent and should be taken
191 seriously ^[22,23]. Total calcium levels are affected by a variety of factors, such as
192 hypoalbuminemia or hypoalbuminemia, and may be less accurate (in the presence of
193 renal disease, acid-base disturbances, or anionic perturbations), even after adjustment
194 by algorithms ^[24-26]. In these cases, iCa measurement may be preferred if feasible and
195 can improve more accurate judgment for the clinician; however, there is a paucity of
196 high-quality studies on iCa and sepsis.

197 In this study, we found that iCa was negatively associated with 28-day mortality
198 from sepsis when it less than 1.14 mmol/L. A retrospective study on elderly patients
199 with sepsis showed that the serum calcium levels of septic patients were lower than
200 those of the control group and that the severity of sepsis was associated with lower
201 serum calcium levels ^[11]. A retrospective study on pediatric sepsis also revealed that
202 among children with sepsis, those with low blood calcium levels had a higher incidence
203 of organ dysfunction than those with normal blood calcium levels ^[11]. These studies
204 increase our confidence in our findings.

205 The normal range of iCa in adults is 1.20–1.40 mmol/L (4.8-5.6 mg/dL) ^[6]. In this
206 study, we found that iCa was below the normal range in most septicemic patients.
207 Furthermore, sepsis mortality was lowest at an iCa level of 1.14 mmol/L, which is
208 slightly below the normal reference range for iCa. This suggests that mild hypocalcemia
209 may be protective against sepsis. A retrospective study ^[27] found that mild
210 hypocalcemia may have a protective effect in septic patients, and calcium
211 supplementation may have both positive and negative effects on mortality depending
212 on the severity of the disease. Aberegg also suggested that low iCa levels may be
213 protective in critically ill patients, whereas attempts to correct low levels may be
214 harmful ^[6]. Our findings are partially consistent with the perspectives of the
215 aforementioned researchers. In a sepsis animal model, calcium supplementation was
216 associated with decreased survival, whereas no deaths were observed in hypocalcemic
217 animals ^[28]. Whether low iCa is a protective mechanism or a consequence of metabolic
218 imbalance in sepsis requires further mechanistic studies. Because of the complex and
219 wide-ranging effects of iCa, this result should be interpreted cautiously.

220 Severe hypercalcemia is associated with an increased risk of death, which is
221 attributable in most cases to primary hyperparathyroidism or malignancy ^[29-31].
222 However, by exploring the nonlinear relationship between iCa and sepsis, we found a
223 significant positive correlation between elevated iCa levels and short-term mortality in
224 patients with sepsis once iCa was greater than 1.14 mmol/L, even if severe
225 hypercalcemia levels were not reached (iCa < 2.5 mmol/L). The mechanism, although
226 not fully delineated, may be due to several factors, including cardiovascular risk.
227 Elevated iCa can lead to increased cardiac load, causing arrhythmias, elevated blood
228 pressure, or increased myocardial contractility, which can further disrupt
229 cardiovascular function in patients with sepsis ^[32-34]. (2) Thrombosis formation:
230 Elevated calcium levels enhance coagulation factor activity and increase blood
231 viscosity, thereby increasing the risk of thrombosis ^[35-37]. (3) Immune dysregulation:
232 Hypercalcemia impairs immune cell function and disrupts immune system regulation,
233 which increases the severity of infection, exacerbates sepsis, and increases the risk of
234 death ^[38,39].

235 Our study has some advantages. First, we used advanced algorithms such as
236 generalized additive modeling (GAM), smoothed curve fitting, and two-segment linear
237 models, which allow for a more accurate determination of the curvilinear and
238 quantitative relationship between iCa and the 28-day risk of death in patients with sepsis.
239 Second, we adjusted for various factors related to short-term prognosis, including
240 demographic information (such as gender, age, race, etc.), Charlson comorbidity index,

241 SOFA score, medication use related to sepsis prognosis (such as steroids, vasopressor
242 antibiotics, etc.), and invasive procedures. This adjustment helps eliminate interference
243 from other factors and makes the results more reliable. Third, we chose to study
244 physiologically active iCa rather than total serum calcium. This is because when
245 patients have fluid overload, chronic diseases, or malnutrition, the total calcium in the
246 plasma may decrease, but the iCa level remains normal. Studying iCa allows for a more
247 accurate assessment of calcium concentration and its correlation with short-term
248 prognosis.

249 However, some limitations should also be discussed. First, our study primarily
250 focused on the evaluation of iCa levels at the time of initial admission to the intensive
251 care unit (ICU), recognizing the potential limitations associated with this single
252 measurement. Nonetheless, we discovered a substantial association between iCa levels
253 and mortality among septic patients. Second, because the data come mainly from
254 patients in the United States, more clinical analysis is needed to test whether our results
255 are applicable to patients with sepsis in other countries. Third, as an observational study,
256 we can only establish associations and cannot determine a causal relationship between
257 iCa and the risk of death from sepsis. Hence, this study should serve as the basis for
258 future well-designed studies to evaluate the impact of iCa counts on mortality and
259 causality.

260 **5. Conclusion**

261 The relationship between iCa and 28-day mortality in patients with sepsis showed
262 a u-shaped curve with an inflection point of 1.14 mmol/L, which is in the range of mild
263 hypocalcemia. When iCa levels were 1.14 mmol/L, each unit increase corresponded to
264 a 79% reduction in the risk of 28-day sepsis mortality. Conversely, when iCa exceeded
265 1.14 mmol/L, each unit increase was linked to an 85% increase in the 28-day mortality
266 risk. These findings are potentially valuable in assessing the prognosis of patients with
267 sepsis and in adjusting the testing and treatment program for patients with sepsis.

268 **Data availability statement**

269 The data are available on the MIMIC-IV database website at [https://mimic-
270 IV.mit.edu/](https://mimic-iv.mit.edu/).

271 **Ethics statement**

272 The data for this study were obtained from the MIMIC-IV public database on the
273 Internet, which has been approved by the institutional review boards of Beth Israel
274 Deaconess Medical Center in Boston, Massachusetts (2001-P-001699/14), and the
275 Massachusetts Institute of Technology (0403000206). Informed consent was abrogated
276 because the data were public and the patients' personal information was uncertain.

277 **Author contributions**

278 All authors read and approved the final manuscript. ZYS were responsible for the
279 study concept and design. CL were responsibility for collecting the data, statistical
280 analysis. HCQ were responsible for literature retrieval. LZY and CYT were responsible
281 for drafting the manuscript. ZFF was responsible for critical reading of a final version
282 of the manuscript.

283 **Funding**

284 Guangzhou municipal science and technology bureau [2023A04J0464]. National
285 Famous Elderly Chinese Medicine Expert Huang Jianling Famous Doctor Inheritance
286 Workshop [Letter of Human Resource Education on Chinese Medicine (2022) No. 75].
287 The National Natural Science Foundation of China [82305164]. Top Talents Project of
288 Guangdong Provincial Hospital of Chinese Medicine (BJ2022YL15).

289 **Conflict of interest**

290 None declared.

291 **Publisher's note**

292 All claims expressed in this article are solely those of the authors and do not
293 necessarily represent those of their affiliated organizations, or those of the publisher,
294 the editors and the reviewers. Any product that may be evaluated in this article, or claim
295 that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

296 **References**

- 297 [1] C.W. Seymour, V.X. Liu, T.J. Iwashyna, et al., Assessment of clinical criteria for sepsis: for the
298 third international consensus definitions for sepsis and septic shock (sepsis-3), *JAMA-J. Am.*
299 *Med. Assoc.* 315 (8) (2016) 762-774, <https://doi.org/10.1001/jama.2016.0288>.
- 300 [2] K.E. Rudd, S.C. Johnson, K.M. Agesa, et al., Global, regional, and national sepsis incidence and
301 mortality, 1990-2017: analysis for the global burden of disease study, *Lancet* 395 (10219) (2020)
302 200-211, [https://doi.org/10.1016/S0140-6736\(19\)32989-7](https://doi.org/10.1016/S0140-6736(19)32989-7).
- 303 [3] M. van den Berg, F.E. van Beuningen, J.C. Ter Maaten, H.R. Bouma, Hospital-related costs of
304 sepsis around the world: a systematic review exploring the economic burden of sepsis, *J. Crit.*
305 *Care* 712022) 154096, <https://doi.org/10.1016/j.jcrc.2022.154096>.
- 306 [4] C. Chiu, M. Legrand, Epidemiology of sepsis and septic shock, *Curr. Opin. Anesthesiol.* 34 (2)
307 (2021) 71-76, <https://doi.org/10.1097/ACO.0000000000000958>.
- 308 [5] R. Luhr, Y. Cao, B. Soderquist, S. Cajander, Trends in sepsis mortality over time in randomised
309 sepsis trials: a systematic literature review and meta-analysis of mortality in the control arm,
310 2002-2016, *Crit. Care* 23 (1) (2019) 241, <https://doi.org/10.1186/s13054-019-2528-0>.
- 311 [6] S.K. Aberegg, Ionized calcium in the icu: should it be measured and corrected? *Chest* 149 (3)
312 (2016) 846-855, <https://doi.org/10.1016/j.chest.2015.12.001>.
- 313 [7] T. Peng, X. Peng, M. Huang, et al., Serum calcium as an indicator of persistent organ failure in

- 314 acute pancreatitis, *Am. J. Emerg. Med.* 35 (7) (2017) 978-982,
315 <https://doi.org/10.1016/j.ajem.2017.02.006>.
- 316 [8] J.K. Sun, W.H. Zhang, L. Zou, et al., Serum calcium as a biomarker of clinical severity and
317 prognosis in patients with coronavirus disease 2019, *Aging (Albany NY)* 12 (12) (2020) 11287-
318 11295, <https://doi.org/10.18632/aging.103526>.
- 319 [9] J.R. Zivin, T. Gooley, R.A. Zager, M.J. Ryan, Hypocalcemia: a pervasive metabolic abnormality
320 in the critically ill, *Am. J. Kidney Dis.* 37 (4) (2001) 689-698, [https://doi.org/10.1016/s0272-6386\(01\)80116-5](https://doi.org/10.1016/s0272-6386(01)80116-5).
- 321
- 322 [10] H. Li, J. Chen, Y. Hu, X. Cai, D. Tang, P. Zhang, Clinical value of serum calcium in elderly
323 patients with sepsis, *Am. J. Emerg. Med.* 52(2022) 208-211,
324 <https://doi.org/10.1016/j.ajem.2021.12.019>.
- 325 [11] Y. Liu, Y. Chai, Z. Rong, Y. Chen, Prognostic value of ionized calcium levels in neonatal sepsis,
326 *Ann. Nutr. Metab.* 76 (3) (2020) 193-200, <https://doi.org/10.1159/000508685>.
- 327 [12] X. Zheng, Y. Li, Q. Cheng, L. Wang, Predictive value of ionized calcium for prognosis of sepsis
328 in very low birth weight infants, *J. Inflamm. Res.* 15(2022) 3749-3760,
329 <https://doi.org/10.2147/JIR.S369431>.
- 330 [13] M. Egi, I. Kim, A. Nichol, et al., Ionized calcium concentration and outcome in critical illness,
331 *Crit. Care Med.* 39 (2) (2011) 314-321, <https://doi.org/10.1097/CCM.0b013e3181ffe23e>.
- 332 [14] D. Yan, X. Xie, X. Fu, et al., U-shaped association between serum calcium levels and 28-day
333 mortality in patients with sepsis: a retrospective analysis of the mimic-iii database, *Shock* 60 (4)
334 (2023) 525-533, <https://doi.org/10.1097/SHK.0000000000002203>.
- 335 [15] A. Johnson, L. Bulgarelli, L. Shen, et al., MIMIC-IV, a freely accessible electronic health record
336 dataset, *Sci. Data* 10 (1) (2023) 1, <https://doi.org/10.1038/s41597-022-01899-x>.
- 337 [16] G. Barber, J. Tanic, A. Leligdowicz, Circulating protein and lipid markers of early sepsis
338 diagnosis and prognosis: a scoping review, *Curr. Opin. Lipidology* 34 (2) (2023) 70-81,
339 <https://doi.org/10.1097/MOL.0000000000000870>.
- 340 [17] A.C. Vazquez, L. Arriaga-Pizano, E. Ferat-Osorio, Cellular markers of immunosuppression in
341 sepsis, *Arch. Med. Res.* 52 (8) (2021) 828-835, <https://doi.org/10.1016/j.arcmed.2021.10.001>.
- 342 [18] L. Bai, S. Sun, Y. Sun, F. Wang, A. Nishiyama, N-type calcium channel and renal injury, *Int.*
343 *Urol. Nephrol.* 54 (11) (2022) 2871-2879, <https://doi.org/10.1007/s11255-022-03183-8>.
- 344 [19] P.D. Nguyen, I. Gooijers, G. Campostrini, et al., Interplay between calcium and sarcomeres
345 directs cardiomyocyte maturation during regeneration, *Science* 380 (6646) (2023) 758-764,
346 <https://doi.org/10.1126/science.abo6718>.
- 347 [20] A. Kelly, M.A. Levine, Hypocalcemia in the critically ill patient, *J. Intensive Care Med.* 28 (3)
348 (2013) 166-177, <https://doi.org/10.1177/0885066611411543>.
- 349 [21] M.B. Gallo, G. Aghagoli, S.L. Hu, C.M. Massoud, L. Robinson-Bostom, Calciphylaxis and
350 kidney disease: a review, *Am. J. Kidney Dis.* 81 (2) (2023) 232-239,
351 <https://doi.org/10.1053/j.ajkd.2022.06.011>.
- 352 [22] A. Sood, G. Singh, T.G. Singh, K. Gupta, Pathological role of the calcium-sensing receptor in
353 sepsis-induced hypotensive shock: therapeutic possibilities and unanswered questions, *Drug Dev.*
354 *Res.* 83 (6) (2022) 1241-1245, <https://doi.org/10.1002/ddr.21959>.
- 355 [23] H. Yang, Z. Zhang, Sepsis-induced myocardial dysfunction: the role of mitochondrial
356 dysfunction, *Inflamm. Res.* 70 (4) (2021) 379-387, <https://doi.org/10.1007/s00011-021-01447-0>.
- 357 [24] I.A. Lian, A. Asberg, Should total calcium be adjusted for albumin? A retrospective observational

358 study of laboratory data from central norway, *BMJ Open* 8 (4) (2018) e017703,
359 <https://doi.org/10.1136/bmjopen-2017-017703>.

360 [25] R.B. Payne, A.J. Little, R.B. Williams, J.R. Milner, Interpretation of serum calcium in patients
361 with abnormal serum proteins, *Br Med J* 4 (5893) (1973) 643-646,
362 <https://doi.org/10.1136/bmj.4.5893.643>.

363 [26] J.D. Smith, S. Wilson, H.G. Schneider, Misclassification of calcium status based on albumin-
364 adjusted calcium: studies in a tertiary hospital setting, *Clin. Chem.* 64 (12) (2018) 1713-1722,
365 <https://doi.org/10.1373/clinchem.2018.291377>.

366 [27] W. He, L. Huang, H. Luo, et al., The positive and negative effects of calcium supplementation on
367 mortality in septic icu patients depend on disease severity: a retrospective study from the mimic-
368 iii, *Crit. Care Res. Pract.* 2022(2022) 2520695, <https://doi.org/10.1155/2022/2520695>.

369 [28] D.S. Malcolm, G.P. Zaloga, J.W. Holaday, Calcium administration increases the mortality of
370 endotoxic shock in rats, *Crit. Care Med.* 17 (9) (1989) 900-903,
371 <https://doi.org/10.1097/00003246-198909000-00012>.

372 [29] T.P. Jacobs, J.P. Bilezikian, Clinical review: rare causes of hypercalcemia, *J. Clin. Endocrinol.*
373 *Metab.* 90 (11) (2005) 6316-6322, <https://doi.org/10.1210/jc.2005-0675>.

374 [30] B. Wang, Y. Gong, B. Ying, B. Cheng, Association of initial serum total calcium concentration
375 with mortality in critical illness, *Biomed Res. Int.* 2018(2018) 7648506,
376 <https://doi.org/10.1155/2018/7648506>.

377 [31] M.I. Hu, Hypercalcemia of malignancy, *Endocrinol. Metabol. Clin. North Amer.* 50 (4) (2021)
378 721-728, <https://doi.org/10.1016/j.ecl.2021.07.003>.

379 [32] G. Bkaily, D. Jacques, Calcium homeostasis, transporters, and blockers in health and diseases of
380 the cardiovascular system, *Int. J. Mol. Sci.* 24 (10) (2023), <https://doi.org/10.3390/ijms24108803>.

381 [33] C.J. Kobylecki, B.G. Nordestgaard, S. Afzal, Plasma ionized calcium and risk of cardiovascular
382 disease: 106 774 individuals from the copenhagen general population study, *Clin. Chem.* 67 (1)
383 (2021) 265-275, <https://doi.org/10.1093/clinchem/hvaa245>.

384 [34] B. Thompson, M. Waterhouse, D.R. English, et al., Vitamin d supplementation and major
385 cardiovascular events: d-health randomised controlled trial, *BMJ-British Medical Journal*
386 381(2023) e075230, <https://doi.org/10.1136/bmj-2023-075230>.

387 [35] T. Koufakis, V. Antonopoulou, M. Grammatiki, et al., The relationship between primary
388 hyperparathyroidism and thrombotic events: report of three cases and a review of potential
389 mechanisms, *Int J Hematol Oncol Stem Cell Res* 12 (3) (2018) 175-180.

390 [36] G. Yorulmaz, A.T. Kalkan, A. Akalin, et al., Effect of hyperparathyroidism on coagulation: a
391 global assessment by modified rotation thromboelastogram (rotem), *Turk. J. Med. Sci.* 51 (6)
392 (2021) 2897-2902, <https://doi.org/10.3906/sag-2012-247>.

393 [37] G. Khattar, F.S. Siddiqui, R. Grovu, et al., The calcium-clot connection: investigating the
394 association between primary hyperparathyroidism and acute venous thromboembolism, *J.*
395 *Thromb. Thrombolysis* 2023), <https://doi.org/10.1007/s11239-023-02906-7>.

396 [38] G.N. Hendy, L. Canaff, Calcium-sensing receptor, proinflammatory cytokines and calcium
397 homeostasis, *Semin. Cell Dev. Biol.* 49(2016) 37-43,
398 <https://doi.org/10.1016/j.semcdb.2015.11.006>.

399 [39] H. Izzedine, T. Chazal, R. Wanchoo, K.D. Jhaveri, Immune checkpoint inhibitor-associated
400 hypercalcaemia, *Nephrol. Dial. Transplant.* 37 (9) (2022) 1598-1608,
401 <https://doi.org/10.1093/ndt/gfaa326>.

iCa (mmol/L)	Q1 (0.21-1.04)	Q2 (1.05-1.12)	Q3 (1.12-1.17)	Q4 (1.18-2.69)	P-value
N	4584	5598	4899	5336	
Age at admission, mean±sd, year	63.22 ± 16.53	66.00 ± 15.59	66.21 ± 15.59	66.99 ± 14.24	<0.001
White, No (%)	2847 (62.11%)	3730 (66.63%)	3347 (68.32%)	3667 (68.72%)	<0.001
Charlson comorbidity index, mean±sd, point	5.86 ± 3.02	6.00 ± 2.96	5.83 ± 2.82	5.93 ± 2.73	0.012
SOFA score, median (min, max)	8.00 (0.00-23.00)	7.00 (0.00-22.00)	6.00 (0.00-20.00)	6.00 (0.00-23.00)	<0.001
Heart rate, mean±sd, Times/minute	110.24 ± 25.12	105.51 ± 24.30	103.35 ± 24.51	102.11 ± 23.59	<0.001
Respiratory rate, mean±sd, Times/minute	27.21 ± 10.09	26.64 ± 9.81	26.47 ± 9.94	26.09 ± 9.77	<0.001
Body temperature, mean±sd, degrees Celsius	36.71 ± 1.51	36.82 ± 1.39	36.75 ± 1.32	36.52 ± 1.33	<0.001
Gender, No (%)					<0.001
Male	2629 (57.35%)	3420 (61.09%)	3038 (62.01%)	3167 (59.35%)	
Female	1955 (42.65%)	2178 (38.91%)	1861 (37.99%)	2169 (40.65%)	
Dexamethasone use, No (%)					<0.001
No	4115 (89.77%)	5040 (90.03%)	4438 (90.59%)	4917 (92.15%)	
Yes	469 (10.23%)	558 (9.97%)	461 (9.41%)	419 (7.85%)	
Dopamine use, No (%)					<0.001
No	4159 (90.73%)	5168 (92.32%)	4554 (92.96%)	5002 (93.74%)	
Yes	425 (9.27%)	430 (7.68%)	345 (7.04%)	334 (6.26%)	
Dobutamine use, No (%)					<0.001
No	4264 (93.02%)	5294 (94.57%)	4689 (95.71%)	5140 (96.33%)	
Yes	320 (6.98%)	304 (5.43%)	210 (4.29%)	196 (3.67%)	
Intravenous gammaglobulin use, No (%)					0.042
No	4454 (97.16%)	5475 (97.80%)	4795 (97.88%)	5226 (97.94%)	
Yes	130 (2.84%)	123 (2.20%)	104 (2.12%)	110 (2.06%)	
Methylprednisolone use, No (%)					0.324
No	3784 (82.55%)	4677 (83.55%)	4109 (83.87%)	4462 (83.62%)	
Yes	800 (17.45%)	921 (16.45%)	790 (16.13%)	874 (16.38%)	
Mechanical Ventilation use, No (%)					0.017
No	1694 (36.95%)	2218 (39.62%)	1892 (38.62%)	1988 (37.26%)	
Yes	2890 (63.05%)	3380 (60.38%)	3007 (61.38%)	3348 (62.74%)	
Hydrocortisone use, No (%)					0.305
No	4488 (97.91%)	5491 (98.09%)	4818 (98.35%)	5247 (98.33%)	
Yes	96 (2.09%)	107 (1.91%)	81 (1.65%)	89 (1.67%)	
Use of carbapenems, No (%)					<0.001
No	3501 (76.37%)	4392 (78.46%)	3927 (80.16%)	4326 (81.07%)	
Yes	1083 (23.63%)	1206 (21.54%)	972 (19.84%)	1010 (18.93%)	
Cephalosporins use, No (%)					0.307
No	4224 (92.15%)	5204 (92.96%)	4516 (92.18%)	4919 (92.19%)	
Yes	360 (7.85%)	394 (7.04%)	383 (7.82%)	417 (7.81%)	
Cillin-based drug use, No (%)					<0.001
No	2008 (43.80%)	2700 (48.23%)	2526 (51.56%)	3070 (57.53%)	
Yes	2576 (56.20%)	2898 (51.77%)	2373 (48.44%)	2266 (42.47%)	
Dialysis use, No (%)					<0.001
No	3952 (86.21%)	5176 (92.46%)	4565 (93.18%)	4990 (93.52%)	
Yes	632 (13.79%)	422 (7.54%)	334 (6.82%)	346 (6.48%)	
Vancomycin use, No (%)					<0.001
No	668 (14.57%)	926 (16.54%)	880 (17.96%)	1149 (21.53%)	
Yes	3916 (85.43%)	4672 (83.46%)	4019 (82.04%)	4187 (78.47%)	
Norepinephrine use, No (%)					<0.001
No	2256 (49.21%)	3275 (58.50%)	3047 (62.20%)	3587 (67.22%)	
Yes	2328 (50.79%)	2323 (41.50%)	1852 (37.80%)	1749 (32.78%)	
28-day mortality, No (%)					<0.001

No	3309 (72.19%)	4552 (81.31%)	4079 (83.26%)	4448 (83.36%)
Yes	1275 (27.81%)	1046 (18.69%)	820 (16.74%)	888 (16.64%)

404 SOFA score: The Sequential Organ Failure Assessment (SOFA) Score.

405 SD: standard deviation.

406
407

Table 2
Results of univariate and multivariable logistic regression analysis.

Exposure	Model 0	Model 1	Model 2	GAM
	OR, 95%CI, <i>P</i> value	OR, 95%CI, <i>P</i> value	OR, 95%CI, <i>P</i> value	OR, 95%CI, <i>P</i> value
iCa (mmol/L)	0.14 (0.11, 0.19) <0.0001	0.13 (0.09, 0.17) <0.0001	0.59 (0.43, 0.82) 0.0014	0.64 (0.46, 0.88) 0.0064
iCa quartile				
Q1	reference	reference	reference	reference
Q2	0.60 (0.54, 0.65) <0.0001	0.57 (0.52, 0.63) <0.0001	0.78 (0.70, 0.87) <0.0001	0.79 (0.71, 0.88) <0.0001
Q3	0.52 (0.47, 0.58) <0.0001	0.50 (0.45, 0.55) <0.0001	0.74 (0.66, 0.83) <0.0001	0.75 (0.67, 0.84) <0.0001
Q4	0.52 (0.47, 0.57) <0.0001	0.50 (0.45, 0.55) <0.0001	0.81 (0.72, 0.90) 0.0002	0.83 (0.74, 0.93) 0.0017
<i>P</i> for trend	<0.0001	<0.0001	<0.0001	0.0009

408
409
410
411
412
413
414


OR: Odds ratio.
95% CI: 95% confidence interval.
Model 0: no covariates were adjusted for.
Model 1: We adjusted only for sex, age at admission, and ethnicity.
Model 2: We adjusted for all covariates presented in Table 1.
GAM: All variables listed in Model II were adjusted. However, continuous variables were adjusted as non-linearity.

415 **Table 3**

416 Explanation of the non-linear association between iCa and the risk of 28-day mortality in sepsis patient.


Outcome:	OR, 95%CI, <i>P</i> value
Fitting model using standard logistic regression	0.59 (0.43, 0.82) 0.0014
Fitting model using two-piecewise linear model	
Inflection point	1.14 (1.12 to 1.15)
\leq inflection point	0.21 (0.13, 0.35) <0.0001
$>$ inflection point	1.85 (1.08, 3.16) 0.0247
Log-likelihood ration test	<0.001

417 The adjustment strategy is the same as model 2 in Table 2.



418

419 **Fig. 1.** Flow chart of patient selection.



420

421 **Fig. 2.**Correlation between iCa levels and 28-day mortality probability in sepsis patients. The solid line
422 represents the smoothed curve, while the dashed line indicates the 95% confidence interval.


Total case from MIMIC-IV database (n=377,207)

342,197 cases with non-septic conditions

35,010 cases remainig


Missing data for ionized calcium data
(n=14,593)

Complete data and included in the analysis
(n=20,417)



The risk of 28-day mortality

0.8
0.6
0.4
0.2



0.5

1.0

1.5

2.0

2.5

The value of basal ionized calcium(mmol/L)